We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor.
- Authors
Chang Hee Jung; Jung Eun Jang; Joong-Yeol Park
- Abstract
Type 2 diabetes mellitus (T2DM) is a complex endocrine and metabolic disorder, and a major public health problem that is rapidly increasing in prevalence. Although a wide range of pharmacotherapies for glycemic control is now available, management of T2DM remains complex and challenging. The kidneys contribute immensely to glucose homeostasis by reabsorbing glucose from the glomerular filtrate. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, a new class of antidiabetic agents that inhibit glucose absorption from the kidney independent of insulin, offer a unique opportunity to improve the outcomes of patients with T2DM. In this review, we provide an overview of two globally-approved SGLT2 inhibitors, dapagliflozin and canagliflozin, and discuss their effects and safety. This information will help clinicians to decide whether these drugs will benefit their patients.
- Subjects
TYPE 2 diabetes treatment; METABOLIC disorders; ENDOCRINE diseases; SODIUM-glucose cotransporters; GLOMERULAR filtration rate; DISEASE prevalence; PUBLIC health
- Publication
Diabetes & Metabolism Journal, 2014, Vol 38, Issue 4, p261
- ISSN
2233-6079
- Publication type
Article
- DOI
10.4093/dmj.2014.38.4.261